Korean VC firm DHP bets on WittGen's AI drug development platform

The signal: WittGen BiotechnologiesDealroom has a profile for this one. Try Dealroom →, classified by Dealroom as an "early growth" stage company specialising in AI-powered single-cell analysis for cancer drug discovery, sits at a specific and technically demanding niche within the broader AI-pharma wave. DHP's cross-border bet suggests that Korean VCs see single-cell-level patient profiling — not just generalised AI drug screening — as a differentiator worth backing, even at a stage where commercial validation remains limited.

Read more: wowtale.net